US04335A1051 - Common Stock
ARVINAS INC
NASDAQ:ARVN (9/6/2024, 8:00:03 PM)
After market: 24.4 0 (0%)24.4
-0.55 (-2.2%)
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 445 full-time employees. The company went IPO on 2018-09-27. The firm uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511
P: 12035351456
CEO: John Houston
Employees: 445
Website: https://www.arvinas.com/
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arvinas (NASDAQ:ARVN) just reported results for the second quarter of 2024.Arvi...
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical...
Here you can normally see the latest stock twits on ARVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: